Xencor XNCR
NASDAQ XNCR
$26.61 -0.01 (-0.04%)
As of: Sep 4, 2026 · 3:59 PM EDT

Xencor (XNCR) Common Equity (2013 - 2026)

Xencor (XNCR) posted quarterly Common Equity of $515.6 million for Q1 2026, down 19.42% year-over-year from $639.9 million in Q1 2025, and down 18.87% quarter-over-quarter from $635.6 million in Q4 2025.

Analysis

Xencor (XNCR) Common Equity (2013 - 2026) Analysis & Trends

Xencor (XNCR) has reported Common Equity for 14 consecutive years, with $515.6 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Common Equity fell 19.42% year-over-year to $515.6 million; the TTM figure through Mar 2026 stood at $515.6 million (down 19.42% YoY), while the FY2025 annual figure was $635.6 million, down 5.7% from the prior year.
  • Common Equity fell to $515.6 million in Q1 2026 per XNCR's latest filing, from $635.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $763.0 million in Q1 2022 and bottomed at $515.6 million in Q1 2026.
  • Historically, Common Equity has averaged $659.7 million across 5 years, with a median of $669.0 million in 2023.
  • Annual changes were most pronounced in 2022 — Common Equity surged 30.74% — and 2026, when it decreased 19.42%.
  • Xencor's Common Equity stood at $727.5 million in 2022, then retreated by 8.99% to $662.1 million in 2023, then rose by 1.8% to $674.0 million in 2024, then fell by 5.7% to $635.6 million in 2025, then slipped by 18.87% to $515.6 million in 2026.
  • Business Quant data shows XNCR's Common Equity at $515.6 million in Q1 2026, $635.6 million in Q4 2025, and $625.3 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 20.25 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 31.71 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 8.42 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 6.76 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.61 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 5.17 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 1.35 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 9.79 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 757.49 Mn
10 Xencor 2.02 Bn 1.65 Bn - 503.23 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 503.23 Mn
Mar 31, 2026 515.63 Mn
Dec 31, 2025 635.59 Mn
Sep 30, 2025 625.32 Mn
Jun 30, 2025 620.35 Mn
Mar 31, 2025 639.87 Mn
Dec 31, 2024 674.03 Mn
Sep 30, 2024 705.93 Mn
Jun 30, 2024 548.71 Mn
Mar 31, 2024 599.73 Mn
Dec 31, 2023 662.09 Mn
Sep 30, 2023 669.01 Mn
Jun 30, 2023 678.88 Mn
Mar 31, 2023 683.58 Mn
Dec 31, 2022 727.50 Mn
Sep 30, 2022 722.70 Mn
Jun 30, 2022 742.34 Mn
Mar 31, 2022 763.02 Mn
Dec 31, 2021 733.50 Mn
Sep 30, 2021 618.86 Mn